If you’re researching BPC-157, start with the question most marketing skips: is it even approved? The short version is no, and the longer version moved in 2026 — though not as far as the headlines suggested. Here’s the plain-English picture.
The simple answer
BPC-157 has never been approved by the FDA as a drug for any use. It hasn’t gone through the large human clinical trials that approval requires. So no one can honestly call it FDA-approved, and any product page implying otherwise is misrepresenting it.
How it ended up “under review”
In 2023, the FDA placed a group of peptides, BPC-157 among them, into a category that effectively blocked them from being compounded while the agency evaluated safety. That’s what put BPC-157 in limbo: not approved, and for a time not compoundable either.
What happened in 2026
The picture shifted this year. In April 2026 the FDA removed BPC-157 from that restricted Category 2 list, and on July 23–24, 2026 its Pharmacy Compounding Advisory Committee voted 8–6 to recommend adding BPC-157 to the 503A list licensed pharmacies may compound — tied to a proposed ulcerative-colitis use. But two things keep this short of “approved”: the panel voted over the objection of the FDA’s own scientists, and the vote is only a recommendation. The agency must still complete formal rulemaking, and it has signaled it may not adopt it. We track every development on our 2026 Updates page.
What this means if you’re curious
“Recommended, not approved” is not “available to buy and use.” Until the FDA actually finalizes a rule, BPC-157 isn’t an approved consumer product, and the accurate, safe move is a conversation with a licensed provider rather than an online vendor.